Interpace Biosciences
New Jersey, United States · Biotechnology, Genetics, Healthcare
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Key facts
- Headquarters
- New Jersey, United States
- Employees
- 107
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (IDXG)
- Website
- respridx.com
- Company page
Recent activity at Interpace Biosciences
- : SEC 8-K (5.01): On August 20, 2026, Interpace Biosciences, Inc. held its 2026 annual meeting of stockholders where two main proposals were approved. The first was to approve an Amended and Restated Certificate of Incorporation with a favorable vote of 24,981,181 shares. The second was to grant the Board discretionary authority to implement a reverse stock split of the Common Stock at a ratio ranging from one-for-two to one-for-ten, which passed with 26,187,509 votes for. This approval allows the Board flexibility to determine the exact ratio, significantly impacting the company's stock structure and potentially its market perception. The meeting was a critical governance activity aimed at enhancing corporate strategy and shareholder value.
- : SEC 8-K (1.02): On December 3, 2025, Interpace Biosciences, Inc. announced the full repayment of its outstanding term loan facility with BroadOak Capital Partners, effectively terminating the agreement before its scheduled maturity date. This repayment signifies a strategic move to reduce debt obligations, thereby improving the company's financial flexibility. The transaction involves a significant financial commitment, although the exact amount of the loan facility is not disclosed in this filing. The early termination of this agreement may positively impact the company's cash flow and operational strategies moving forward.
- : Interpace Biosciences Announces Capital Restructuring with Investors for Uplisting to Nasdaq
- : INTERPACE BIOSCIENCES, INC.
- : Interpace Diagnostics Group, Inc.
- : Interpace Diagnostics Group, Inc.
Interpace Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2020 | Venture | $47.0M |
| Jul 2019 | Venture | $14.0M |
| Jan 2017 | Pre-Seed | $111K |
Leadership
- Fortunato Rocca, Director
- Edward Chan, Director
- Robert Gorman, Director
- Laurence McCarthy, Director
- Eric Lev, Director
- Felice Schnoll-Sussman, Director
- Stephen Sullivan, Director
- Joseph Keegan, Director
- Jack Stover, Executive Officer, Director
- Eric Lev, Director
- Felice Schnoll-Sussman, Director
- Stephen Sullivan, Director
Verified email and direct lines for Interpace Biosciences’s decision-makers are on Fundz. See plans
Employee benefit plans
Interpace Biosciences files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Interpace Biosciences
- Devyser · Biotechnology, Genetics, Health Care, Health Diagnostics
- Exosome Diagnostics · Biotechnology, Healthcare, Health Care, Health Diagnostics
- Passage Bio · Biotechnology, Genetics, Healthcare, Health Care
- DermTech, Inc. · Biotechnology, Genetics, Healthcare, Health Care
- Geneoscopy · Biotechnology, Healthcare, Health Care, Health Diagnostics
About Interpace Biosciences: questions and answers
What does Interpace Biosciences do?
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Where is Interpace Biosciences headquartered?
Interpace Biosciences is headquartered in New Jersey, United States.
How many employees does Interpace Biosciences have?
Interpace Biosciences has about 107 employees.
Has Interpace Biosciences raised funding?
Yes. Fundz has recorded 3 funding events for Interpace Biosciences. The most recent, $47.0M, was in Jan 2020.
What is the latest news on Interpace Biosciences?
On Aug 20, 2026, SEC 8-K (5.01): On August 20, 2026, Interpace Biosciences, Inc. held its 2026 annual meeting of stockholders where two main proposals were approved. The first was to approve an Amended and Restated Certificate of Incorporation with a favorable vote of 24,981,181 shares. The second was to grant the B
Is Interpace Biosciences a public company?
Yes. Interpace Biosciences is publicly traded under the ticker IDXG.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy